LLY.BA Eli Lilly and Company
Company Analysis
Latest News
🟢 LLY.BA is trading 2.1% up today on the launch of Medicare GLP-1 Bridge program
Eli Lilly's stock is up 2.1% today at $34,600 following the launch of its Medicare GLP-1 Bridge program. • The program, effective July 1, 2026, significantly...
🔴 LLY.BA is trading 2.3% down today on profit-taking after recent gains
LLY.BA is trading 2.3% down at $33,220.00 as the stock pulls back following a period of strong momentum and no new company-specific news. • The move is...
🟢 LLY.BA is trading 0.9% up today after positive EU regulatory opinion for Jaypirca
LLY.BA is trading at $33660.00 (+0.90%) as sentiment remains constructive following a key regulatory milestone for Jaypirca in the European Union. • The EMA’s...
Eli Lilly Wins EU Backing for Jaypirca, Targeting Chronic Leukemia
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Eli Lilly’s leukemia drug, Jaypirca....
Lilly Unlocks Medicare's 14 Million Obesity Patients at $50 a Month — But Can Volume Overcome the Price Trade-Off?
Shares surged 6.4% to $33,100 (LLY.BA) as Eli Lilly detailed exactly how seniors will get its weight-loss drugs for just $50 a month starting July 1 — even as...
🟢 LLY.BA is trading 6.4% up today as Eli Lilly sets $50 Medicare copay for obesity drugs
LLY.BA is trading 6.4% up at $33100.00 after Eli Lilly announced that Medicare Part D beneficiaries will be able to access Zepbound and Foundayo for $50 per...
Eli Lilly details $50 Medicare weight-loss plan for Zepbound and Foundayo
Eli Lilly released details for its Medicare GLP-1 Bridge program starting July 1, 2026. This initiative provides Medicare Part D beneficiaries access to...
🟢 LLY.BA is trading 2.3% up today after $1.9B Abbisko deal and Centessa acquisition
LLY.BA is trading 2.3% up today at $31,600.00 following a string of bullish corporate developments, including a major R&D collaboration and strategic...
🟢 LLY.BA is trading 2.2% up today on news of a major R&D deal, Centessa acquisition completion, and AI investment
• Eli Lilly announced a significant R&D and licensing collaboration with China's Abbisko Therapeutics, potentially worth up to $1.9 billion, to develop novel...
🟢 Eli Lilly and Company is trading 2.03% up today after announcing a neurodegeneration partnership and Q3 dividend
Eli Lilly and Company is trading 2.03% up at $30,200.00, following significant company-specific developments. • The company announced a strategic collaboration...
🔴 Eli Lilly and Company is trading 2.8% down today as profit-taking extends multi-day slide
Eli Lilly and Company is trading 2.8% down at $28,780.00, extending a multi-day slide from $30,340.00 on June 15 as investors lock in recent gains. • No fresh...
Eli Lilly Jaypirca Cuts Leukemia Progression Risk 45%, Beating Standard Care
Eli Lilly announced positive results from its Phase 3 BRUIN CLL-322 trial for Jaypirca (pirtobrutinib). Adding Jaypirca to a standard treatment of venetoclax...
Lilly Advances AJX-101, Showing Success in Treatment-Resistant Myelofibrosis Patients
Eli Lilly and Company reported Phase 1 data for its investigational type II JAK2 inhibitor at the 2026 European Hematology Association (EHA) Annual Meeting....